Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $900,000.

  • Foghorn Therapeutics' Depreciation & Amortization (CF) rose 28.57% to $900,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 3.46%. This contributed to the annual value of $3.1 million for FY2024, which is 10.86% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $900,000 for Q3 2025, which was down 0.00% from $900,000 recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Depreciation & Amortization (CF) registered a high of $900,000 during Q3 2022, and its lowest value of $700,000 during Q3 2024.
  • For the 3-year period, Foghorn Therapeutics' Depreciation & Amortization (CF) averaged around $834,727, with its median value being $835,000 (2024).
  • Per our database at Business Quant, Foghorn Therapeutics' Depreciation & Amortization (CF) spiked by 300.00% in 2021 and then fell by 22.22% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $810,000 in 2021, then rose by 1.36% to $821,000 in 2022, then grew by 9.62% to $900,000 in 2023, then dropped by 20.00% to $720,000 in 2024, then grew by 28.57% to $900,000 in 2025.
  • Its Depreciation & Amortization (CF) was $900,000 in Q3 2025, compared to $900,000 in Q2 2025 and $827,000 in Q1 2025.